Literature DB >> 8835747

Stimulation of bile acid 6 alpha-hydroxylation by rifampin.

H Wietholtz1, H U Marschall, J Sjövall, S Matern.   

Abstract

BACKGROUND: Rifampin was shown to relieve pruritus in cholestatic liver diseases. There has been much speculation about the origin of pruritus, but it has not yet been comprehensively explained. The role of bile acids in producing pruritus is obscure and still under debate. Since rifampin both inhibits the uptake of bile acids into the hepatocyte and strongly induces mixed-function oxidases in the liver, the beneficial effects of this drug might be a consequence of altered bile acid metabolism.
METHODS: We investigated the influence of rifampin on urinary bile acid excretion with special respect to glucuronide and sulphate conjugates in 14 healthy volunteers before and after administration of rifampin, 600 mg x 7 days, using each subject as his or her own control.
RESULTS: Bile acid glucuronide excretion increased from 0.55 to 1.19 mumol/24 h. This was in particular due to a significant increase of the urinary excretion of the 6 alpha-hydroxylated hyocholic and hyodeoxycholic acids, the relative amounts of which accounted for about two thirds of the urinary bile acid excretion. Excretion of sulphates, however, decreased from 1.40 to 0.86 mumol/24 h due to a significantly reduced excretion of lithocholic acid sulphate. No changes in the excretion rates of other primary and secondary bile acids and no changes in their conjugation patterns were observed.
CONCLUSIONS: The results provide evidence that rifampin induces 6 alpha-hydroxylation of bile acids. The products are subsequently glucuronidated at the 6 alpha-hydroxy group, thus stimulating renal excretion of potentially toxic bile acids.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8835747     DOI: 10.1016/s0168-8278(96)80268-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  17 in total

1.  Rifampicin and treatment of cholestatic pruritus.

Authors:  A F Hofmann
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 2.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

Review 3.  New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.

Authors:  James L Boyer
Journal:  J Hepatol       Date:  2006-12-18       Impact factor: 25.083

4.  An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.

Authors:  W Xie; A Radominska-Pandya; Y Shi; C M Simon; M C Nelson; E S Ong; D J Waxman; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

5.  The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity.

Authors:  J L Staudinger; B Goodwin; S A Jones; D Hawkins-Brown; K I MacKenzie; A LaTour; Y Liu; C D Klaassen; K K Brown; J Reinhard; T M Willson; B H Koller; S A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

6.  Rifampicin, not vitamin E, suppresses parenteral nutrition-associated liver disease development through the pregnane X receptor pathway in piglets.

Authors:  Gregory Guthrie; Barbara Stoll; Shaji Chacko; Charlotte Lauridsen; Jogchum Plat; Douglas Burrin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-10-11       Impact factor: 4.052

7.  Upregulation of UGT2B4 Expression by 3'-Phosphoadenosine-5'-Phosphosulfate Synthase Knockdown: Implications for Coordinated Control of Bile Acid Conjugation.

Authors:  Kathleen G Barrett; Hailin Fang; Daniela Cukovic; Alan A Dombkowski; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Drug Metab Dispos       Date:  2015-05-06       Impact factor: 3.922

Review 8.  Current management of primary sclerosing cholangitis in pediatric patients.

Authors:  Samar H Ibrahim; Keith D Lindor
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 9.  The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.

Authors:  Jiezhong Chen; Kong-Nan Zhao; Chen Chen
Journal:  Ann Transl Med       Date:  2014-01

10.  New paradigms of USP53 disease: normal GGT cholestasis, BRIC, cholangiopathy, and responsiveness to rifampicin.

Authors:  Hamoud Alhebbi; Abdul Ali Peer-Zada; Abdulrahman A Al-Hussaini; Sara Algubaisi; Awad Albassami; Nasser AlMasri; Yasir Alrusayni; Ibrahim M Alruzug; Essa Alharby; Manar A Samman; Syed Zubair Ayoub; Sateesh Maddirevula; Roy W A Peake; Fowzan S Alkuraya; Sami Wali; Naif A M Almontashiri
Journal:  J Hum Genet       Date:  2020-08-06       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.